Gene Transfer of Mutant Mouse Cholinesterase Provides High Lifetime Expression and Reduced Cocaine Responses with No Evident Toxicity

• Liyi Geng,

  Affiliation Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Yang Gao,

  Affiliation Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Xiabin Chen,

  Affiliation Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America

  ⨯
• Shurong Hou,

  Affiliation Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America

  ⨯
• Chang-Guo Zhan,

  Affiliation Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America

  ⨯
• Zoran Radic,

  Affiliation Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, LaJolla, California, United States of America

  ⨯
• Robin J. Parks,

  Affiliation Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

  ⨯
• Stephen J. Russell,

  Affiliation Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Linh Pham,

  Affiliation Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Stephen Brimijoin

  * E-mail: brimijoin@mayo.edu

  Affiliation Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯